Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis

Advances in Parasitology

Volumn 94, Issue , 2016, Pages 393-417

  Kastner, R J ^a,b   Stone, C M ^a,b   Steinmann, P ^a,b   Tanner, M ^a,b   Tediosi, F ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Elimination and eradication of infectious diseases; EPIFIL; Eradication investment case; Global Malaria Eradication Programme; Global Programme to Eliminate Lymphatic Filariasis; Incremental cost effectiveness ratio; Lymphatic filariasis; Mass drug administration; Mathematical modelling

Indexed keywords

ANTHELMINTIC AGENT;

ANTIHELMINTHIC THERAPY; ARTICLE; COST CONTROL; ERADICATION THERAPY; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LYMPHATIC FILARIASIS; NONHUMAN; PARASITE CLEARANCE; PRIORITY JOURNAL; PRODUCTIVITY; PROGRAM COST EFFECTIVENESS; PROGRAM FEASIBILITY; SOCIAL JUSTICE; ANIMAL; BRUGIA; COST BENEFIT ANALYSIS; DISEASE ERADICATION; DRUG EFFECTS; ECONOMICS; ELEPHANTIASIS, FILARIAL; THEORETICAL MODEL;

ANIMALS; ANTHELMINTICS; BRUGIA; COST-BENEFIT ANALYSIS; DISEASE ERADICATION; ELEPHANTIASIS, FILARIAL; HUMANS; MODELS, THEORETICAL;

EID: 84992152155     PISSN: 0065308X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.apar.2016.08.004     Document Type: Article

References (76)

1. Anderson, R.M., May, R.M., Helminth infections of humans: mathematical models, population dynamics, and control. Adv. Parasitol. 24 (1985), 1–101.
2. Anderson, R.M., May, R.M., Infectious Diseases of Humans: Dynamics and Control. 1992, Oxford University Press, Oxford.
3. Andrews, J.M., Langmuir, A.D., The philosophy of disease eradication. Am. J. Public Health Nations Health 53 (1963), 1–6.
4. Anonymous, Guinea worm disease nears eradication. Lancet Infect. Dis., 16, 2016, 131.
5. Azoh Barry, J., Social sciences research on infectious diseases of poverty: too little and too late?. PLoS Negl. Trop. Dis., 8, 2014, e2803.
6. Babu, B.V., Mishra, S., Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Trans. R. Soc. Trop. Med. Hyg. 102 (2008), 1207–1213.
7. 0 for vector-borne diseases with a periodic vector population. Bull. Math. Biol. 69 (2007), 1067–1091.
8. Bailey, T.C., Merritt, M.W., Tediosi, F., Investing in justice: ethics, evidence, and the eradication investment cases for lymphatic filariasis and onchocerciasis. Am. J. Public Health 105 (2015), 629–636.
9. Cano, J., Rebollo, M.P., Golding, N., Pullan, R.L., Crellen, T., Soler, A., Kelly-Hope, L.A., Lindsay, S.W., Hay, S.I., Bockarie, M.J., Brooker, S.J., The global distribution and transmission limits of lymphatic filariasis: past and present. Parasit. Vectors, 7, 2014, 466.
10. Cantey, P.T., Rao, G., Rout, J., Fox, L.M., Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008. Trop. Med. Int. Health 15 (2010), 224–231.
11. Chan, M.S., Srividya, A., Norman, R.A., Pani, S.P., Ramaiah, K.D., Vanamail, P., Michael, E., Das, P.K., Bundy, D.A., Epifil: a dynamic model of infection and disease in lymphatic filariasis. Am. J. Trop. Med. Hyg. 59 (1998), 606–614.
12. Chippaux, J.P., Boussinesq, M., Gardon, J., Gardon-Wendel, N., Ernould, J.C., Severe adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areas. Parasitol. Today 12 (1996), 448–450.
13. Chu, B.K., Hooper, P.J., Bradley, M.H., McFarland, D.A., Ottesen, E.A., The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007). PLoS Negl. Trop. Dis., 4, 2010, e708.
14. Cochi, S.C., Disease Eradication in the Context of Global Health in the 21st Century. August 29–September 3, 2010, Frankfurt am Main, Germany Available: http://www.esforum.de/forums/esf07_disease_eradication.html.
15. Dobson, A., Climate variability, global change, immunity, and the dynamics of infectious diseases. Ecology 90 (2009), 920–927.
16. Dowdle, W.R., The principles of disease elimination and eradication. Bull. World Health Organ. 76 (1998), 22–25.
17. El Setouhy, M., Ramzy, R.M., Ahmed, E.S., Kandil, A.M., Hussain, O., Farid, H.A., Helmy, H., Weil, G.J., A randomized clinical trial comparing single- and multi-dose combination therapy with diethylcarbamazine and albendazole for treatment of bancroftian filariasis. Am. J. Trop. Med. Hyg. 70 (2004), 191–196.
18. Esterre, P., Plichart, C., Sechan, Y., Nguyen, N.L., The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Trop. Med. Int. Health 6 (2001), 190–195.
19. Gambhir, M., Bockarie, M., Tisch, D., Kazura, J., Remais, J., Spear, R., Michael, E., Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis. BMC Biol., 8, 2010, 22.
20. Gambhir, M., Singh, B.K., Michael, E., The Allee effect and elimination of neglected tropical diseases: a mathematical modelling study. Adv. Parasitol. 87 (2015), 1–31.
21. Gardon, J., Gardon-Wendel, N., Demanga-Ngangue, Kamgno, J., Chippaux, J.P., Boussinesq, M., Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350 (1997), 18–22.
22. Gass, K., Beau de Rochars, M.V.E., Boakye, D., Bradley, M., Fischer, P.U., Gyapong, J., Itoh, M., Ituaso-Conway, N., Joseph, H., Kyelem, D., Laney, S.J., Legrand, A.-M., Liyanage, T.S., Melrose, W., Mohammed, K., Pilotte, N., Ottesen, E.A., Plichart, C., Ramaiah, K., Rao, R.U., Talbot, J., Weil, G.J., Williams, S.A., Won, K.Y., Lammie, P., A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis. PLoS Negl. Trop. Dis., 6, 2012, e1479.
23. Gladwell, M., Fred Soper and the Global Malaria Eradication Programme. J. Public Health Policy 23 (2002), 479–497.
24. Hairston, N.G., de Meillon, B., On the inefficiency of transmission of Wuchereria bancrofti from mosquito to human host. Bull. World Health Organ. 38 (1968), 935–941.
25. Hasibeder, G., Dye, C., Population dynamics of mosquito-borne disease: persistence in a completely heterogeneous environment. Theor. Popul. Biol. 33 (1988), 31–53.
26. Henderson, D.A., Klepac, P., Lessons from the eradication of smallpox: an interview with D.A. Henderson. Philos. Trans. R. Soc. Lond. B Biol. Sci., 368, 2013, 20130113.
27. Hoerauf, A., Volkmann, L., Nissen-Paehle, K., Schmetz, C., Autenrieth, I., Büttner, D.W., Fleischer, B., Targeting of Wolbachia endobacteria in Litomosoides sigmodontis: comparison of tetracyclines with chloramphenicol, macrolides and ciprofloxacin. Trop. Med. Int. Health 5 (2000), 275–279.
28. Hoerauf, A., Pfarr, K., Mand, S., Debrah, A.Y., Specht, S., Filariasis in Africa–treatment challenges and prospects. Clin. Microbiol. Infect. 17 (2011), 977–985.
29. Hyman, J.M., Li, J., An intuitive formulation for the reproductive number for the spread of diseases in heterogeneous populations. Math. Biosci. 167 (2000), 65–86.
30. Ichimori, K., King, J.D., Engels, D., Yajima, A., Mikhailov, A., Lammie, P., Ottesen, E.A., Global Programme to Eliminate Lymphatic Filariasis: the processes underlying programme success. PLoS Negl. Trop. Dis., 8, 2014, e3328.
31. Kastner, R.J., Stone, C.M., Steinmann, P., Tanner, M., Tediosi, F., What is needed to eradicate lymphatic filariasis? A model-based assessment on the impact of scaling up mass drug administration programs. PLoS Negl. Trop. Dis., 9, 2015, e0004147.
32. Kim, Y.E., Remme, J.H., Steinmann, P., Stolk, W.A., Roungou, J.B., Tediosi, F., Correction: control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. PLoS Negl. Trop. Dis., 9, 2015, e0003777.
33. Kim, Y.E., Sicuri, E., Tediosi, F., Financial and economic costs of the elimination and eradication of onchocerciasis (river blindness) in Africa. PLoS Negl. Trop. Dis., 9, 2015, e0004056.
34. Lymphatic Filariasis: Managing Morbidity and Preventing Disability, 2013, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/85347/1/9789241505291_eng.pdf.
35. Mak, J.W., Yen, P.K., Lim, K.C., Ramiah, N., Zoonotic implications of cats and dogs in filarial transmission in Peninsular Malaysia. Trop. Geogr. Med. 32 (1980), 259–264.
36. May, R.M., Togetherness among schistosomes: its effects on the dynamics of the infection. Math. Biosci. 35 (1977), 301–343.
37. Moutou, F., The second eradication: rinderpest. Bull. Soc. Pathol. Exot. 107 (2014), 137–138 135–136.
38. Murray, C.J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A.D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J.A., Abdalla, S., Aboyans, V., Abraham, J., Ackerman, I., Aggarwal, R., Ahn, S.Y., Ali, M.K., Alvarado, M., Anderson, H.R., Anderson, L.M., Andrews, K.G., Atkinson, C., Baddour, L.M., Bahalim, A.N., Barker-Collo, S., Barrero, L.H., Bartels, D.H., Basáñez, M.G., Baxter, A., Bell, M.L., Benjamin, E.J., Bennett, D., Bernabe, E., Bhalla, K., Bhandari, B., Bikbov, B., Bin Abdulhak, A., Birbeck, G., Black, J.A., Blencowe, H., Blore, J.D., Blyth, F., Bolliger, I., Bonaventure, A., Boufous, S., Bourne, R., Boussinesq, M., Braithwaite, T., Brayne, C., Bridgett, L., Brooker, S., Brooks, P., Brugha, T.S., Bryan-Hancock, C., Bucello, C., Buchbinder, R., Buckle, G., Budke, C.M., Burch, M., Burney, P., Burstein, R., Calabria, B., Campbell, B., Canter, C.E., Carabin, H., Carapetis, J., Carmona, L., Cella, C., Charlson, F., Chen, H., Cheng, A.T., Chou, D., Chugh, S.S., Coffeng, L.E., Colan, S.D., Colquhoun, S., Colson, K.E., Condon, J., Connor, M.D., Cooper, L.T., Corriere, M., Cortinovis, M., de Vaccaro, K.C., Couser, W., Cowie, B.C., Criqui, M.H., Cross, M., Dabhadkar, K.C., Dahiya, M., Dahodwala, N., Damsere-Derry, J., Danaei, G., Davis, A., De Leo, D., Degenhardt, L., Dellavalle, R., Delossantos, A., Denenberg, J., Derrett, S., Des Jarlais, D.C., Dharmaratne, S.D., Dherani, M., Diaz-Torne, C., Dolk, H., Dorsey, E.R., Driscoll, T., Duber, H., Ebel, B., Edmond, K., Elbaz, A., Ali, S.E., Erskine, H., Erwin, P.J., Espindola, P., Ewoigbokhan, S.E., Farzadfar, F., Feigin, V., Felson, D.T., Ferrari, A., Ferri, C.P., Fevre, E.M., Finucane, M.M., Flaxman, S., Flood, L., Foreman, K., Forouzanfar, M.H., Fowkes, F.G., Fransen, M., Freeman, M.K., Gabbe, B.J., Gabriel, S.E., Gakidou, E., Ganatra, H.A., Garcia, B., Gaspari, F., Gillum, R.F., Gmel, G., Gonzalez-Medina, D., Gosselin, R., Grainger, R., Grant, B., Groeger, J., Guillemin, F., Gunnell, D., Gupta, R., Haagsma, J., Hagan, H., Halasa, Y.A., Hall, W., Haring, D., Haro, J.M., Harrison, J.E., Havmoeller, R., Hay, R.J., Higashi, H., Hill, C., Hoen, B., Hoffman, H., Hotez, P.J., Hoy, D., Huang, J.J., Ibeanusi, S.E., Jacobsen, K.H., James, S.L., Jarvis, D., Jasrasaria, R., Jayaraman, S., Johns, N., Jonas, J.B., Karthikeyan, G., Kassebaum, N., Kawakami, N., Keren, A., Khoo, J.P., King, C.H., Knowlton, L.M., Kobusingye, O., Koranteng, A., Krishnamurthi, R., Laden, F., Lalloo, R., Laslett, L.L., Lathlean, T., Leasher, J.L., Lee, Y.Y., Leigh, J., Levinson, D., Lim, S.S., Limb, E., Lin, J.K., Lipnick, M., Lipshultz, S.E., Liu, W., Loane, M., Ohno, S.L., Lyons, R., Mabweijano, J., MacIntyre, M.F., Malekzadeh, R., Mallinger, L., Manivannan, S., Marcenes, W., March, L., Margolis, D.J., Marks, G.B., Marks, R., Matsumori, A., Matzopoulos, R., Mayosi, B.M., McAnulty, J.H., McDermott, M.M., McGill, N., McGrath, J., Medina-Mora, M.E., Meltzer, M., Mensah, G.A., Merriman, T.R., Meyer, A.C., Miglioli, V., Miller, M., Miller, T.R., Mitchell, P.B., Mock, C., Mocumbi, A.O., Moffitt, T.E., Mokdad, A.A., Monasta, L., Montico, M., Moradi-Lakeh, M., Moran, A., Morawska, L., Mori, R., Murdoch, M.E., Mwaniki, M.K., Naidoo, K., Nair, M.N., Naldi, L., Narayan, K.M., Nelson, P.K., Nelson, R.G., Nevitt, M.C., Newton, C.R., Nolte, S., Norman, P., Norman, R., O'Donnell, M., O'Hanlon, S., Olives, C., Omer, S.B., Ortblad, K., Osborne, R., Ozgediz, D., Page, A., Pahari, B., Pandian, J.D., Rivero, A.P., Patten, S.B., Pearce, N., Padilla, R.P., Perez-Ruiz, F., Perico, N., Pesudovs, K., Phillips, D., Phillips, M.R., Pierce, K., Pion, S., Polanczyk, G.V., Polinder, S., Pope, C.A. 3rd, Popova, S., Porrini, E., Pourmalek, F., Prince, M., Pullan, R.L., Ramaiah, K.D., Ranganathan, D., Razavi, H., Regan, M., Rehm, J.T., Rein, D.B., Remuzzi, G., Richardson, K., Rivara, F.P., Roberts, T., Robinson, C., De Leon, F.R., Ronfani, L., Room, R., Rosenfeld, L.C., Rushton, L., Sacco, R.L., Saha, S., Sampson, U., Sanchez-Riera, L., Sanman, E., Schwebel, D.C., Scott, J.G., Segui-Gomez, M., Shahraz, S., Shepard, D.S., Shin, H., Shivakoti, R., Singh, D., Singh, G.M., Singh, J.A., Singleton, J., Sleet, D.A., Sliwa, K., Smith, E., Smith, J.L., Stapelberg, N.J., Steer, A., Steiner, T., Stolk, W.A., Stovner, L.J., Sudfeld, C., Syed, S., Tamburlini, G., Tavakkoli, M., Taylor, H.R., Taylor, J.A., Taylor, W.J., Thomas, B., Thomson, W.M., Thurston, G.D., Tleyjeh, I.M., Tonelli, M., Towbin, J.A., Truelsen, T., Tsilimbaris, M.K., Ubeda, C., Undurraga, E.A., van der Werf, M.J., van Os, J., Vavilala, M.S., Venketasubramanian, N., Wang, M., Wang, W., Watt, K., Weatherall, D.J., Weinstock, M.A., Weintraub, R., Weisskopf, M.G., Weissman, M.M., White, R.A., Whiteford, H., Wiebe, N., Wiersma, S.T., Wilkinson, J.D., Williams, H.C., Williams, S.R., Witt, E., Wolfe, F., Woolf, A.D., Wulf, S., Yeh, P.H., Zaidi, A.K., Zheng, Z.J., Zonies, D., Lopez, A.D., AlMazroa, M.A., Memish, Z.A., Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2197–2223.
39. Nájera, J.A., González-Silva, M., Alonso, P.L., Some lessons for the future from the Global Malaria Eradication Programme (1955–1969). PLoS Med., 8, 2011, e1000412.
40. Nandha, B., Sadanandane, C., Jambulingam, P., Das, P., Delivery strategy of mass annual single dose DEC administration to eliminate lymphatic filariasis in the urban areas of Pondicherry, South India: 5 years of experience. Filaria J., 6, 2007, 7.
41. Norman, R.A., Chan, M.S., Srividya, A., Pani, S.P., Ramaiah, K.D., Vanamail, P., Michael, E., Das, P.K., Bundy, D.A., EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis. Epidemiol. Infect. 124 (2000), 529–541.
42. Nutman, T.B., Lymphatic Filariasis. 2012, Geneva, Switzerland: World Health Organization, Geneva, Switzerland Available: http://www.who.int/mediacentre/factsheets/fs102/en/.
43. Ottesen, E.A., Lymphatic filariasis: treatment, control and elimination. Adv. Parasitol. 61 (2006), 395–441.
44. Ottesen, E.A., Duke, B.O., Karam, M., Behbehani, K., Strategies and tools for the control/elimination of lymphatic filariasis. Bull. World Health Organ. 75 (1997), 491–503.
45. Ottesen, E.A., Dowdle, W.R., Fenner, F., Habermehl, K.-O., John, T.J., Koch, M.A., Medley, G.F., Muller, A.S., Ostroff, S.M., Zeichhardt, H., Group Report: How Is Eradication to Be Defined and What Are the Biological Criteria. 1997 In: The Eradication of Infectious Diseases. W. R. Dowdle, D. Hopkins (Eds), Wiley, 238 pp.
46. Paily, K.P., Hoti, S.L., Das, P.K., A review of the complexity of biology of lymphatic filarial parasites. J. Parasit. Dis. 33 (2009), 3–12.
47. Plaisier, A.P., van Oortmarssen, G.J., Remme, J., Alley, E.S., Habbema, J.D., The risk and dynamics of onchocerciasis recrudescence after cessation of vector control. Bull. World Health Organ. 69 (1991), 169–178.
48. Preventive Chemotherapy Databank Lymphatic Filariasis, 2015, WHO, Geneva. Available: http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/.
49. Provisional Strategy for Interrupting Lymphatic Filariasis Transmission in Loiasis-Endemic Countries, 2012, World Health Organization Available: http://www.who.int/neglected_diseases/NTD_STAG_Report_2010.pdf.
50. Ramaiah, K.D., Das, P.K., Appavoo, N.C., Ramu, K., Augustin, D.J., Kumar, K.N., Chandrakala, A.V., A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Trop. Med. Int. Health 5 (2000), 842–847.
51. Ramaiah, K.D., Das, P.K., Vanamail, P., Pani, S.P., Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis. Trans. R. Soc. Trop. Med. Hyg. 101 (2007), 555–563.
52. Rebollo, M.P., Sambou, S.M., Thomas, B., Biritwum, N.-K., Jaye, M.C., Kelly-Hope, L., Escalada, A.G., Molyneux, D.H., Bockarie, M.J., Elimination of lymphatic filariasis in The Gambia. PLoS Negl. Trop. Dis., 9, 2015, e0003642.
53. Recommendations of the International Task Force for Disease Eradication. MMWR Recomm. Rep. 42 (1993), 1–38.
54. Rudge, J.W., Webster, J.P., Lu, D.B., Wang, T.P., Fang, G.R., Basáñez, M.G., Identifying host species driving transmission of Schistosomiasis japonica, a multihost parasite system, in China. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 11457–11462.
55. Santatiwongchai, B., Chantarastapornchit, V., Wilkinson, T., Thiboonboon, K., Rattanavipapong, W., Walker, D.G., Chalkidou, K., Teerawattananon, Y., Methodological variation in economic evaluations conducted in low- and middle-income countries: information for reference case development. PLoS One, 10, 2015, e0123853.
56. Sicuri, E., Evans, D.B., Tediosi, F., Can economic analysis contribute to disease elimination and eradication? A systematic review. PLoS One, 10, 2015, e0130603.
57. Smith, T., Schapira, A., Reproduction numbers in malaria and their implications. Trends Parasitol. 28 (2012), 3–8.
58. Steinmann, P., Stone, C.M., Sutherland, C.S., Tanner, M., Tediosi, F., Contemporary and emerging strategies for eliminating human African trypanosomiasis due to Trypanosoma brucei gambiense: review. Trop. Med. Int. Health 20 (2015), 707–718.
59. Stolk, W.A., Stone, C., de Vlas, S.J., Modelling lymphatic filariasis transmission and control: modelling frameworks, lessons learned and future directions. Adv. Parasitol. 87 (2015), 249–291.
60. Stone, C.M., Kastner, R., Steinmann, P., Chitnis, N., Tanner, M., Tediosi, F., Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage. BMJ Glob. Health, 1, 2016.
61. Strebel, P.M., Cochi, S.L., Hoekstra, E., Rota, P.A., Featherstone, D., Bellini, W.J., Katz, S.L., A world without measles. J. Infect. Dis. 204 (2011), S1–S3.
62. Subramanian, S., Stolk, W.A., Ramaiah, K.D., Plaisier, A.P., Krishnamoorthy, K., Van Oortmarssen, G.J., Dominic Amalraj, D., Habbema, J.D., Das, P.K., The dynamics of Wuchereria bancrofti infection: a model-based analysis of longitudinal data from Pondicherry, India. Parasitology 128 (2004), 467–482.
63. Sugiyama, H., Yamaguchi, A., Murakami, H., Japanese Corporate Initiatives in Global Health: Case Studies and Policy Recommendations. 2012, Global Health Policy Center. H.a.G.P. Institute, Tokyo, Japan.
64. Sutherland, C.S., Stone, C., Tediosi, F., Health systems modelling – demonstrating the potential impact of diagnostic and treatment integration of human African trypanosomiasis using different health system structures. BMC Health Serv. Res., 14, 2014 P122.
65. Taylor, M.J., Bandi, C., Hoerauf, A., Wolbachia bacterial endosymbionts of filarial nematodes. Adv. Parasitol. 60 (2005), 245–284.
66. Taylor, M.J., Hoerauf, A., Bockarie, M., Lymphatic filariasis and onchocerciasis. Lancet 376 (2010), 1175–1185.
67. Tediosi, F., Steinmann, P., de Savigny, D., Tanner, M., Developing eradication investment cases for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis: rationale and main challenges. PLoS Negl. Trop. Dis., 7, 2013, e2446.
68. The Carter Center, Diseases Considered as Candidates for Global Eradication by the International Task Force for Disease Eradicationas as updated in April 2008 by the Centers for Disease Control (CDC). Available: https://www.cartercenter.org/resources/pdfs/news/health_publications/itfde/updated_disease_candidate_table.pdf.
69. The Carter Center, Eradication and Elimination Programs Currently Sanctioned by the World Health Organization. 2016 Available: http://www.cartercenter.org/health/itfde/who.htm.
70. Thompson, K.M., Tebbens, R.J., Eradication versus control for poliomyelitis: an economic analysis. Lancet 369 (2007), 1363–1371.
71. Thomsen, E.K., Sanuku, N., Baea, M., Satofan, S., Maki, E., Lombore, B., Schmidt, M.S., Siba, P.M., Weil, G.J., Kazura, J.W., Fleckenstein, L.L., King, C.L., Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin. Infect. Dis. 62 (2016), 334–341.
72. Ton, T.G., Mackenzie, C., Molyneux, D.H., The burden of mental health in lymphatic filariasis. Infect. Dis. Poverty, 4, 2015, 34.
73. Uniting to Combat Neglected Tropical Diseases, The London Declaration. Ending the Neglect and Reaching 2020 Goals. 2012 Available: http://unitingtocombatntds.org/resource/london-declaration.
74. Walker, M., Specht, S., Churcher, T.S., Hoerauf, A., Taylor, M.J., Basáñez, M.G., Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. Clin. Infect. Dis. 60 (2015), 1199–1207.
75. Webster, J.P., Gower, C.M., Knowles, S.C., Molyneux, D.H., Fenton, A., One health – an ecological and evolutionary framework for tackling Neglected Zoonotic Diseases. Evol. Appl. 9 (2016), 313–333.
76. World Health Organization, Global Programme to Eliminate Lymphatic Filariasis. 2016 Available: http://www.who.int/lymphatic_filariasis/disease/en/.